Sugammadex and Smoker's Neuromuscular Block

Phase 4

Completed

• Conditions: Smoking; Neuromuscular Blockade
• Interventions: Drug: sugammadex

• Registration Number: NCT05313100
• Lead Sponsor: Duzce University

Brief Summary

We compared the durations of antagonizing and of the severity of effect of sugammadex used in antagonizing the rocuronium in smoker and non-smoker total 40 patients with using Train of Four(TOF) neuromuscular monitorization.

Detailed Description

40 patients from American Society of Anesthesiologist (ASA) I- II class, being smokers for at least 10 years or non-smokers, who will undergo elective surgery were included in this randomized prospective study. Patients underwent routine monitoring and neuromuscular monitoring. Propofol 2 mg/kg and intravenous fentanyl 1 mcg/kg were applied at induction. After the loss of eyelash reflex, intravenous rocuronium 0,6 mg/kg was administered. The patient was intubated at a Train of Four count of 2. Anesthesia was continued with 50% O2 + 50% air and sevoflurane 2 % . Rocuronium 0,15 mg/kg was administered when TOF (Train of Four) counter reached 2 during the operation. Sugammadex 2 mg/kg was administered at the end of the operation. The time to reach Train of Four values of 0,7-0,8-0,9 were recorded.

Study Timeline

• Study Start: 2012-04
• Primary Completion: 2013-01
• Study Completion: 2013-08
• Study First Submitted: 2015-08-06
• Study First Submitted QC: 2022-03-28
• Status Verified: 2022-04
• Study First Posted: 2022-04-06
• Last Update Submitted: 2022-04-11
• Last Update Posted: 2022-04-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• Elective surgery,
• 1-2 according to the ASA ( American Society of Anesthesiologist ) physical status classification.
• Patients who have smoked at least 10 packs or have been smoking for 10 years and currently smoking
• Or never smoked patients

Read More

Exclusion Criteria

• neuromuscular diseases
• radiotherapy and/or chemotherapy anamnesis,
• liver and/or renal disease,
• electrolyte balance,
• history of drug use which affects neuromuscular transmission,
• Body Mass Index (BMI) of more than 27,
• use alcohol

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Smokers	sugammadex	The patients who have smoked at least 10 packs or have been smoking for 10 years and currently smoking were included in the smoker group At the end of operation for reversal of neuromuscular blockade sugammadex used.
Nonsmokers	sugammadex	The patients who never smoked were included in the non-smoker group At the end of operation for reversal of neuromuscular blockade sugammadex used.

Primary Outcome Measures

Name	Time	Method
Neuromuscular block recovery time	six months	Time to reach TOF %90 measurement after given neuromuscular blocker reverse agent